Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients

被引：56

作者：

Panza, Francesco ^{[1
,2
,3
]}

Seripa, Davide ^{[3
]}

Solfrizzi, Vincenzo ^{[4
,5
]}

Imbimbo, Bruno P. ^{[6
,7
]}

Lozupone, Madia ^{[1
]}

Leo, Antonio ^{[1
]}

Sardone, Rodolfo ^{[8
]}

Gagliardi, Gaetano ^{[1
]}

Lofano, Lucia ^{[9
]}

Creanza, Bianca C. ^{[10
]}

Bisceglia, Paola ^{[3
,4
]}

Daniele, Antonio ^{[11
]}

Bellomo, Antonello ^{[12
]}

Greco, Antonio ^{[3
,4
]}

Logroscino, Giancarlo ^{[1
,2
]}

机构：

[1] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Unit Neurodegenerat Dis, Bari, Italy

[2] Univ Bari Aldo Moro, Pia Fdn Card G Panico, Dept Clin Res Neurol, Unit Neurodegenerat Dis, Lecce, Italy

[3] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Geriatr Unit, Foggia, Italy

[4] IRCCS Casa Sollievo Sofferenza, Dept Med Sci, Gerontol Geriatr Res Lab, Foggia, Italy

[5] Univ Bari Aldo Moro, Geriatr Med Memory Unit, Bari, Italy

[6] Univ Bari Aldo Moro, Rare Dis Ctr, Bari, Italy

[7] Chiesi Farmaceut, Res & Dev Dept, Parma, Italy

[8] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Biomed Engn Unit, Bari, Italy

[9] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, Psychiatr Unit, Bari, Italy

[10] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Inst Neurol, Rome, Italy

[12] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy

来源：

EXPERT OPINION ON EMERGING DRUGS | 2016年 / 21卷 / 04期

关键词：

Monoclonal antibodies; aducanumab; solanezumab; gantenerumab; BACE inhibitors; verubecestat; ALZT-OP1; azeliragon; Alzheimer's disease; dementia; cognitive disorders; GLYCATION END-PRODUCTS; A-BETA; CLINICAL-TRIALS; DOUBLE-BLIND; MOUSE MODEL; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; MONOCLONAL-ANTIBODIES; NATIONAL INSTITUTE; INHIBITOR THERAPY;

D O I：

10.1080/14728214.2016.1241232

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Currently available drugs against Alzheimer's disease (AD) target cholinergic and gluta-matergic neurotransmissions without affecting the underlying disease process. Putative disease-modifying drugs are in development and target 3-amyloid (A beta) peptide and tau protein, the principal neurophatological hallmarks of the disease. Areas covered: Phase III clinical studies of emerging anti-A beta drugs for the treatment of AD were searched in US and EU clinical trial registries and in the medical literature until May 2016. Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the beta-secretase cleaving enzyme (BACE) (verubecestat), three anti-A beta monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1). These drugs are mainly being tested in subjects during early phases of AD or in subjects at preclinical stage of familial AD or even in asymptomatic subjects at high risk of developing AD. The hope is to intervene in the disease process when it is not too late. However, previous clinical failures with anti-AP drugs and the lack of fully understanding of the pathophysiological role of AP in the development of AD, put the new drugs at substantial risk of failure.

引用

页码：377 / 391

页数：15

共 130 条

[1] Simvastatin Therapy Prevents Brain Trauma-Induced Increases in β-Amyloid Peptide Levels [J].